News - Thoreauchem

2018 CPHI Shanghai on June,waiting for your visit

Published

2018-04-28

Our Anqin branch company will attend the exhibition CPHI in Shanghai on June this year Welcome to our company's booth and make a better understanding of each other. Our booth number is W3F16 ,waiting for your coming.

Read More

Good news!!! The establishment of the Anqing branch of Thoreauchem Limited.

Published

2018-01-31

It is our honor to share the exciting news for he establishment of the Anqing branch of Thoreauchem Limited. We currently has nearly 400 square meters in Nanjing development area, and 1300 square meters in Anqing city,Anhui province, equipped with a full ...

Read More

European Commission Approves Amgen's IMLYGIC™ (talimogene laherparepvec) As First Oncolytic Immunotherapy In Europe

Published

2015-12-23

Amgen today announced that the European Commission has approved the use of IMLYGIC™ (talimogene laherparepvec) for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a), with no bone, ...

Read More

FDA approves first recombinant von Willebrand factor to treat bleeding episodes

Published

2015-12-10

The U.S. Food and Drug Administration today approve Vonvendi,von Willebrand factor (Recombinant), for use in adults 18 years of age and older who have von Willebrand disease (VWD).Vonvendi is the first FDA-approved recombinant von Willebrand factor, and ...

Read More

Horizon Pharma plc Receives European Commission Approval for RAVICTI(R) (glycerol phenylbutyrate) Oral Liquid for the Treatment of Urea Cycle Disorders in Patients Two Months of Age and Olde

Published

2015-12-09

Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, and its affiliate, ...

Read More

FDA approves Empliciti, a new immune-stimulating therapy to treat multiple myeloma

Published

2015-12-01

Today the U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications. Multiple myeloma is a form of blood ...

Read More

Stepped-up Nucynta sales push starts paying off for Depomed

Published

2015-11-18

Depomed's ($DEPO) relaunch of the Nucynta franchise--purchased earlier this year from Johnson & Johnson ($JNJ)--is off to a running start, the company said last week with its Q3 earnings announcement. And it expects that momentum to carry it all the way ...

Read More

Catalent stops production at French plant, brings in law enforcement after it twice detects tampering

Published

2015-11-18

U.S.-based Catalent ($CTLT) has halted production at a softgel capsule manufacturing facility in France at the request of regulators after several incidents in which it appears someone within the plant purposely mixed the wrong capsules into batches. The ...

Read More

GSK Announces Positive Results From Phase III BLISS-SC Study of Benlysta(R) (Belimumab) Administered Subcutaneously In Patients With Systemic Lupus Erythematosus (SLE)

Published

2015-11-13

GSK announced results from the BLISS-SC Phase III pivotal study in patients with active, autoantibody-positive systemic lupus erythematosus (SLE). These results, which are being presented at the American College of Rheumatology/Association for ...

Read More

Amgen Presents Detailed Results From Phase 3 Study Demonstrating Clinical Equivalence Of Biosimilar Candidate ABP 501 With Adalimumab

Published

2015-11-12

THOUSAND OAKS, CA, USA I November 9, 2015 I Amgen (NASDAQ:AMGN) today presented detailed findings from a head-to-head Phase 3 study comparing the safety, efficacy and immunogenicity of biosimilar candidate ABP 501 with adalimumab in patients with ...

Read More

FDA Approves COTELLIC™ (Cobimetinib) for use in Combination with Vemurafenib to Treat Advanced Melanoma

Published

2015-11-12

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved COTELLIC™ (cobimetinib) as a treatment for patients with BRAF V600E or V600K mutation-positive ...

Read More

Collegium Announces FDA Tentative Approval for Xtampza(TM) ER, a Novel Abuse-Deterrent Analgesic for Chronic Pain

Published

2015-11-11

CANTON, MA, USA I November 9, 2015 I Collegium Pharmaceutical, Inc. (COLL) today announced that the United States Food and Drug Administration (FDA) has granted tentative approval to the Company's New Drug Application (NDA) for Xtampza(TM) ER (oxycodone) ...

Read More

Lilly and Incyte Announce Patients Treated with Baricitinib Demonstrated Significant Improvement in Signs and Symptoms of Rheumatoid Arthritis Compared with Methotrexate

Published

2015-11-10

INDIANAPOLIS, IN, USA I November 7, 2015 I Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announce detailed data from the pivotal phase 3 RA-BEGIN study, which show investigational baricitinib alone and in combination were ...

Read More

Samsung Bioepis' SB4 and SB2 Investigational Biosimilar Candidates Sustain Comparable Safety Profiles in One-Year Phase 3 Clinical Studies

Published

2015-11-10

I Samsung Bioepis Co., Ltd. announced that SB4 etanercept and SB2 infliximab investigational biosimilar candidates sustained comparable safety profiles in 52- and 54-week clinical studies, respectively. Equally important, SB5 adalimumab investigational ...

Read More

Allergan Outlines Open Science Model And Highlights Key Development Programs At R&D Day

Published

2015-11-09

llergan plc (NYSE: AGN), a leading global pharmaceutical company, today hosted its R&D day where the Company outlined its 'Open Science' R&D model that is helping to build therapy area leadership and drive the Company's long-term growth. The meeting also ...

Read More

FDA approves new treatment for HIV

Published

2015-11-09

The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and ...

Read More

Merck KGaA, Darmstadt, Germany, and Pfizer Announce Initiation of Phase III First-Line Trial of Avelumab in Patients with Recurrent or Stage IV Non-Small Cell Lung Cancer

Published

2015-11-06

From Pfiizer website DARMSTADT, Germany & NEW YORK--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, and Pfizer today announced the initiation of an international Phase III study of the investigational cancer immunotherapy avelumab* in a treatment naïve ...

Read More

FDA Approves New Drug for Heart Failure

Published

2015-07-16

THURSDAY, July 9, 2015 (HealthDay News) -- The U.S. Food and Drug Administration has approved the first in a new class of drugs that show promise for combating heart failure. The approval of Entresto (sacubitril/varsatan) was sped up after a clinical ...

Read More

FDA Strengthens Warning on NSAIDs and Heart Risk

Published

2015-07-16

July 10, 2015 -- Popular painkillers like ibuprofen and naproxen have carried warnings for years about potential risks of heart attacks and strokes. This week, the FDA decided to strengthen those warnings on the medications, known as nonsteroidal ...

Read More

Roche's subcutaneous Herceptin gets EU green light

Published

2013-07-04

(Reuters) - Swiss drugmaker Roche said on Friday that European regulators had given a green light to a new formulation of its breast cancer drug Herceptin, which it hopes will help extend the medicine's shelf life. The European Medicines Agency (EMA) ...

Read More

FDA Safety Communication: Boxed Warning on increased mortality and severe renal injury, and additional warning on risk of bleeding, for use of hydroxyethyl starch solutions in some settings

Published

2013-06-19

Purpose FDA has analyzed recent data that indicate an increased risk of (i) mortality and renal injury requiring renal replacement therapy in critically ill adult patients, including patients with sepsis and those admitted to the ICU; and (ii) excess ...

Read More

EMA advisory committee gives thumbs-up to fenofibrate/simvastatin combo

Published

2013-06-19

London, UK - The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) is recommending that a combination tablet of fenofibrate/simvastatin (Cholib, Abbott Healthcare, Abbott Park, IL) be approved as an adjunct to ...

Read More